Valsartan
- Atc Codes:C09CA03
- CAS Codes:137862-53-4
- PHARMGKB ID:137862-53-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Angiosan, Diovan, Valsacor, Valsartan, Valsavil; Belgium: Diovane; Bulgaria: Cezoryn, Diovan, Nortivan, Sarteg, Valtensin; Cyprus: Diovan; Czech Republic: Cezoryn, Diovan, Kylotan, Valaric, Valsabela, Valsacor, Valsartan, Valzap; Denmark: Diovan, Tareg; Estonia: Diovan, Nortivan, Valsacor, Valsol, Valzap; Finland: Diovan; France: Nisis, Tareg; Germany: Cordinate, Diovan, Provas, Valsartan; Greece: Avalsan, Diovan, Valsartan; Hungary: Diovan, Valsacor, Valsartan; Ireland: Diotev, Diovan, Valsartan, Valsotens; Italy: Tareg; Latvia: Diovan; Lithuania: Diovan, Nortivan, Valaric, Valsacor, Valsartan, Valsol; Luxembourg: Diovan; Netherlands: Diovan, Tareg, Tifival, Valsartan, Valsabio, Valsavil; Poland: Anartan, Bespres, Cezoryn, Diovan, Metrival, Nortivan, Nuclaval, Tensart, Valitazin, Valpress, Valsacor, Valsartan, Valzek, Yosovaltan, Zelvartan; Portugal: Diovan, Tareg, Valsartan, Vatan; Romania: Coreton, Diovan, Valaric, Valsacor, Valsartan, Valsol; Slovakia: Cezoryn, Diovan, Vararic, Valsacor, Valsartan, Vasopentol; Slovenia: Diovan, Valsacor, Valsartan, Valsol; Spain: Diován, Klapress, Miten, Vals, Valsartán; Sweden: Angiosan, Diovan, Tareg, Valsartan; UK: Diovan.
North America
Canada: Diovan; USA: Diovan.
Latin America
Argentina: Alpertán, Corosán-Merck, Diován, Racorval, Sarval, Simultán, Valsartán; Brazil: Diovan; Mexico: Diován.
Asia
Japan: Diovan.
Drug combinations
Valsartan and Aliskiren
Valsartan and Amlodipine
Valsartan and Hydrochlorothiazide
Valsartan, Amlodipine, and Hydrochlorothiazide
Chemistry
Valsartan: C~24~H~29~N~5~O~3~. Mw: 435.52. (1) L-Valine, N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-; (2) N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine. CAS-137862-53-4 (1995).
Pharmacologic Category
Angiotensin II Receptor Antagonists. (ATC-Code: C09CA03).
Mechanism of action
Displaces angiotensin II from AT~1~ receptor and produces its blood pressure-lowering effects by antagonizing AT~1~-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses.
Therapeutic use
Treatment of essential hypertension (alone or in combination with other antihypertensive agents). Reduction of cardiovascular mortality in left ventricular dysfunction postmyocardial infarction. Treatment of heart failure.
Pregnancy and lactiation implications
Medications which act on angiotensin system can cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters. Unknown whether valsartan is excreted in breast milk.
Unlabeled use
Contraindications
Hypersensitivity to valsartan or any component of the formulation.
Warnings and precautions
Hyperkalemia may occur (use with caution in renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts). Hypotension may occur, particularly in heart failure or post-myocardial infarct patients. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in low renal blood flow (e.g. renal artery stenosis, heart failure). Small increases in serum creatinine may occur. Use caution in significant aortic/mitral stenosis, when initiating in heart failure (due to valsartan-induced hypotension), and in significant hepatic impairment (clearance significantly reduced). Avoid use or use smaller dose in hypovolemia. Use with caution in unstented unilateral/bilateral renal artery stenosis. Use generally avoided in unstented bilateral renal artery stenosis due to elevated risk of deterioration in renal function. Use with caution with pre-existing renal insufficiency and severe renal impairment. Use not approved in patients <18 years of age. Angiotensin receptor blockers should be discontinued as soon as possible once pregnancy is detected.